APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Viral Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174046500322 December 2025187 pages

Choose your research edition.

Industry ResearchViral Vector Vaccines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector Vaccines Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Viral Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vector Vaccines Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Viral Vector Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Viral Vector Vaccines include Advanced Bioscience Laboratories, Boehringer Ingelheim, Brammer Bio, Creative Biogene, GE Healthcare, Pfizer and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Viral Vector Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vector Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vector Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Viral Vector Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Viral Vector Vaccines Segment by Company

Advanced Bioscience Laboratories

Boehringer Ingelheim

Brammer Bio

Creative Biogene

GE Healthcare

Pfizer

Sanofi

Viral Vector Vaccines Segment by Type

Adenovirus

Fowlpox Virus

Vaccinia Virus Vectors

Attenuated Yellow Fever

Others

Viral Vector Vaccines Segment by Application

Hospitals

Clinics

Others

Viral Vector Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Viral Vector Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Viral Vector Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Viral Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Viral Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Viral Vector Vaccines Industry Trends Table 2. Viral Vector Vaccines Industry Drivers Table 3. Viral Vector Vaccines Industry Opportunities and Challenges Table 4. Viral Vector Vaccines Industry Restraints Table 5. Global Viral Vector Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Viral Vector Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Viral Vector Vaccines Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Viral Vector Vaccines Sales Market Share by Manufacturers Table 9. Global Viral Vector Vaccines Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Viral Vector Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Viral Vector Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Viral Vector Vaccines Manufacturers, Product Type & Application Table 13. Global Viral Vector Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Viral Vector Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Adenovirus Table 17. Major Manufacturers of Fowlpox Virus Table 18. Major Manufacturers of Vaccinia Virus Vectors Table 19. Major Manufacturers of Attenuated Yellow Fever Table 20. Major Manufacturers of Others Table 21. Global Viral Vector Vaccines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 23. Global Viral Vector Vaccines Sales by Type (2027-2032) & (k units) Table 24. Global Viral Vector Vaccines Sales Market Share by Type (2021-2026) Table 25. Global Viral Vector Vaccines Sales Market Share by Type (2027-2032) Table 26. Global Viral Vector Vaccines Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Viral Vector Vaccines Revenue by Type (2021-2026) & (k units) Table 28. Global Viral Vector Vaccines Revenue by Type (2027-2032) & (k units) Table 29. Global Viral Vector Vaccines Revenue Market Share by Type (2021-2026) Table 30. Global Viral Vector Vaccines Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Clinics Table 33. Major Manufacturers of Others Table 34. Global Viral Vector Vaccines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 36. Global Viral Vector Vaccines Sales by Application (2027-2032) & (k units) Table 37. Global Viral Vector Vaccines Sales Market Share by Application (2021-2026) Table 38. Global Viral Vector Vaccines Sales Market Share by Application (2027-2032) Table 39. Global Viral Vector Vaccines Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Viral Vector Vaccines Revenue by Application (2021-2026) & (k units) Table 41. Global Viral Vector Vaccines Revenue by Application (2027-2032) & (k units) Table 42. Global Viral Vector Vaccines Revenue Market Share by Application (2021-2026) Table 43. Global Viral Vector Vaccines Revenue Market Share by Application (2027-2032) Table 44. Global Viral Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Viral Vector Vaccines Sales by Region (2021-2026) & (k units) Table 46. Global Viral Vector Vaccines Sales Market Share by Region (2021-2026) Table 47. Global Viral Vector Vaccines Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Viral Vector Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 51. North America Viral Vector Vaccines Sales by Country (2027-2032) & (k units) Table 52. Europe Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 54. Europe Viral Vector Vaccines Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Viral Vector Vaccines Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Viral Vector Vaccines Sales by Country (2027-2032) & (k units) Table 61. Global Viral Vector Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Viral Vector Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Viral Vector Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Viral Vector Vaccines Revenue Market Share by Region (2021-2026) Table 65. Global Viral Vector Vaccines Revenue Market Share by Region (2027-2032) Table 66. Advanced Bioscience Laboratories Company Information Table 67. Advanced Bioscience Laboratories Business Overview Table 68. Advanced Bioscience Laboratories Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Advanced Bioscience Laboratories Viral Vector Vaccines Product Portfolio Table 70. Advanced Bioscience Laboratories Recent Development Table 71. Boehringer Ingelheim Company Information Table 72. Boehringer Ingelheim Business Overview Table 73. Boehringer Ingelheim Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Boehringer Ingelheim Viral Vector Vaccines Product Portfolio Table 75. Boehringer Ingelheim Recent Development Table 76. Brammer Bio Company Information Table 77. Brammer Bio Business Overview Table 78. Brammer Bio Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Brammer Bio Viral Vector Vaccines Product Portfolio Table 80. Brammer Bio Recent Development Table 81. Creative Biogene Company Information Table 82. Creative Biogene Business Overview Table 83. Creative Biogene Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Creative Biogene Viral Vector Vaccines Product Portfolio Table 85. Creative Biogene Recent Development Table 86. GE Healthcare Company Information Table 87. GE Healthcare Business Overview Table 88. GE Healthcare Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. GE Healthcare Viral Vector Vaccines Product Portfolio Table 90. GE Healthcare Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pfizer Viral Vector Vaccines Product Portfolio Table 95. Pfizer Recent Development Table 96. Sanofi Company Information Table 97. Sanofi Business Overview Table 98. Sanofi Viral Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Sanofi Viral Vector Vaccines Product Portfolio Table 100. Sanofi Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Viral Vector Vaccines Distributors List Table 104. Viral Vector Vaccines Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Viral Vector Vaccines Product Image Figure 2. Global Viral Vector Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vector Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Vector Vaccines Sales (2021-2032) & (k units) Figure 5. Global Viral Vector Vaccines Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Viral Vector Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Adenovirus Image Figure 9. Fowlpox Virus Image Figure 10. Vaccinia Virus Vectors Image Figure 11. Attenuated Yellow Fever Image Figure 12. Others Image Figure 13. Global Viral Vector Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Viral Vector Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Viral Vector Vaccines Sales Market Share by Type (2021-2032) Figure 16. Global Viral Vector Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Viral Vector Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Viral Vector Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Others Image Figure 22. Global Viral Vector Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Viral Vector Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Viral Vector Vaccines Sales Market Share by Application (2021-2032) Figure 25. Global Viral Vector Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Viral Vector Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Viral Vector Vaccines Revenue Market Share by Application (2021-2032) Figure 28. North America Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Viral Vector Vaccines Sales Market Share by Country (2021-2032) Figure 30. U.S. Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Viral Vector Vaccines Sales Market Share by Country (2021-2032) Figure 35. Germany Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Viral Vector Vaccines Sales Market Share by Country (2021-2032) Figure 42. China Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Viral Vector Vaccines Sales Market Share by Country (2021-2032) Figure 50. Brazil Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Viral Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Viral Vector Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Viral Vector Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Viral Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. North America Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Viral Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. Europe Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Viral Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Viral Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Viral Vector Vaccines Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Viral Vector Vaccines Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Adenovirus
  • Fowlpox Virus
  • Vaccinia Virus Vectors
  • Attenuated Yellow Fever
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Advanced Bioscience Laboratories
  • Boehringer Ingelheim
  • Brammer Bio
  • Creative Biogene
  • GE Healthcare
  • Pfizer
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Viral Vector Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Viral Vector Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Viral Vector Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Viral Vector Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Viral Vector Vaccines Market Dynamics
  1. 2.1 Viral Vector Vaccines Industry Trends
  2. 2.2 Viral Vector Vaccines Industry Drivers
  3. 2.3 Viral Vector Vaccines Industry Opportunities and Challenges
  4. 2.4 Viral Vector Vaccines Industry Restraints
3 Viral Vector Vaccines Market by Manufacturers
  1. 3.1 Global Viral Vector Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Viral Vector Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Viral Vector Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Viral Vector Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Viral Vector Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Viral Vector Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Viral Vector Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Viral Vector Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Viral Vector Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Viral Vector Vaccines Tier 1, Tier 2, and Tier 3
4 Viral Vector Vaccines Market by Type
  1. 4.1 Viral Vector Vaccines Type Introduction
  2. 4.1.1 Adenovirus
  3. 4.1.2 Fowlpox Virus
  4. 4.1.3 Vaccinia Virus Vectors
  5. 4.1.4 Attenuated Yellow Fever
  6. 4.1.5 Others
  7. 4.2 Global Viral Vector Vaccines Sales by Type
  8. 4.2.1 Global Viral Vector Vaccines Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Viral Vector Vaccines Sales by Type (2021-2032)
  10. 4.2.3 Global Viral Vector Vaccines Sales Market Share by Type (2021-2032)
  11. 4.3 Global Viral Vector Vaccines Revenue by Type
  12. 4.3.1 Global Viral Vector Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Viral Vector Vaccines Revenue by Type (2021-2032)
  14. 4.3.3 Global Viral Vector Vaccines Revenue Market Share by Type (2021-2032)
5 Viral Vector Vaccines Market by Application
  1. 5.1 Viral Vector Vaccines Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Viral Vector Vaccines Sales by Application
  6. 5.2.1 Global Viral Vector Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Viral Vector Vaccines Sales by Application (2021-2032)
  8. 5.2.3 Global Viral Vector Vaccines Sales Market Share by Application (2021-2032)
  9. 5.3 Global Viral Vector Vaccines Revenue by Application
  10. 5.3.1 Global Viral Vector Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Viral Vector Vaccines Revenue by Application (2021-2032)
  12. 5.3.3 Global Viral Vector Vaccines Revenue Market Share by Application (2021-2032)
6 Global Viral Vector Vaccines Sales by Region
  1. 6.1 Global Viral Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Vector Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Viral Vector Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Viral Vector Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Viral Vector Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Viral Vector Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Viral Vector Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Viral Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Viral Vector Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Viral Vector Vaccines Revenue by Region
  1. 7.1 Global Viral Vector Vaccines Revenue by Region
  2. 7.1.1 Global Viral Vector Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Viral Vector Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Viral Vector Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Viral Vector Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Viral Vector Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Viral Vector Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Viral Vector Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Viral Vector Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Viral Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Advanced Bioscience Laboratories
  2. 8.1.1 Advanced Bioscience Laboratories Company Information
  3. 8.1.2 Advanced Bioscience Laboratories Business Overview
  4. 8.1.3 Advanced Bioscience Laboratories Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Advanced Bioscience Laboratories Viral Vector Vaccines Product Portfolio
  6. 8.1.5 Advanced Bioscience Laboratories Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim Viral Vector Vaccines Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Brammer Bio
  14. 8.3.1 Brammer Bio Company Information
  15. 8.3.2 Brammer Bio Business Overview
  16. 8.3.3 Brammer Bio Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Brammer Bio Viral Vector Vaccines Product Portfolio
  18. 8.3.5 Brammer Bio Recent Developments
  19. 8.4 Creative Biogene
  20. 8.4.1 Creative Biogene Company Information
  21. 8.4.2 Creative Biogene Business Overview
  22. 8.4.3 Creative Biogene Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Creative Biogene Viral Vector Vaccines Product Portfolio
  24. 8.4.5 Creative Biogene Recent Developments
  25. 8.5 GE Healthcare
  26. 8.5.1 GE Healthcare Company Information
  27. 8.5.2 GE Healthcare Business Overview
  28. 8.5.3 GE Healthcare Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GE Healthcare Viral Vector Vaccines Product Portfolio
  30. 8.5.5 GE Healthcare Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Viral Vector Vaccines Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Viral Vector Vaccines Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Viral Vector Vaccines Value Chain Analysis
  2. 9.1.1 Viral Vector Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Viral Vector Vaccines Production Mode & Process
  6. 9.2 Viral Vector Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Viral Vector Vaccines Distributors
  9. 9.2.3 Viral Vector Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst